Persistently moderate DAS-28 is not benign: loss of function occurs in early RA despite step-up DMARD therapy.

@article{Conaghan2010PersistentlyMD,
  title={Persistently moderate DAS-28 is not benign: loss of function occurs in early RA despite step-up DMARD therapy.},
  author={Philip G Conaghan and Elizabeth M. A. Hensor and A L Keenan and Ann W Morgan and P T J Emery},
  journal={Rheumatology},
  year={2010},
  volume={49 10},
  pages={1894-9}
}
OBJECTIVES Current UK management of RA initially employs conventional DMARDs, with biological therapy reserved for DMARD-resistant RA patients with persistently high 28-joint disease activity score (DAS-28). The aim of this study was to examine the effect on patient-reported function of persistently moderate DAS-28 despite modern step-up DMARD therapy in an early arthritis cohort. METHODS Data were obtained from the Yorkshire Early Arthritis Register, a cohort of early (<12 months) RA… CONTINUE READING